274 related articles for article (PubMed ID: 33603751)
1. Warburg Effect Is a Cancer Immune Evasion Mechanism Against Macrophage Immunosurveillance.
Chen J; Cao X; Li B; Zhao Z; Chen S; Lai SWT; Muend SA; Nossa GK; Wang L; Guo W; Ye J; Lee PP; Feng M
Front Immunol; 2020; 11():621757. PubMed ID: 33603751
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor cell-to-macrophage communication by blocking Vtn-C1qbp interaction inhibits tumor progression via enhancing macrophage phagocytosis.
Zhang C; Liu Y; Jiang J; Chen C; Duan Z; Su H; Wang S; Tian B; Shi Y; Xiang R; Luo Y
Theranostics; 2024; 14(7):2757-2776. PubMed ID: 38773982
[No Abstract] [Full Text] [Related]
3. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
5. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
[TBL] [Abstract][Full Text] [Related]
6. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-Enabled Dual Modulation of Phagocytic Signals to Improve Macrophage-Mediated Cancer Immunotherapy.
Zhang YR; Luo JQ; Zhang JY; Miao WM; Wu JS; Huang H; Tong QS; Shen S; Leong KW; Du JZ; Wang J
Small; 2020 Nov; 16(46):e2004240. PubMed ID: 33107142
[TBL] [Abstract][Full Text] [Related]
8. Restoration of miR-340 controls pancreatic cancer cell
Xi Q; Zhang J; Yang G; Zhang L; Chen Y; Wang C; Zhang Z; Guo X; Zhao J; Xue Z; Li Y; Zhang Q; Da Y; Liu L; Yao Z; Zhang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32503944
[TBL] [Abstract][Full Text] [Related]
9. SLAMF3 and SLAMF4 are immune checkpoints that constrain macrophage phagocytosis of hematopoietic tumors.
Li D; Xiong W; Wang Y; Feng J; He Y; Du J; Wang J; Yang M; Zeng H; Yang YG; Wu N; Chen S; Dong Z
Sci Immunol; 2022 Jan; 7(67):eabj5501. PubMed ID: 35061505
[TBL] [Abstract][Full Text] [Related]
10. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
11. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
[TBL] [Abstract][Full Text] [Related]
13. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
14. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.
Rao L; Wu L; Liu Z; Tian R; Yu G; Zhou Z; Yang K; Xiong HG; Zhang A; Yu GT; Sun W; Xu H; Guo J; Li A; Chen H; Sun ZJ; Fu YX; Chen X
Nat Commun; 2020 Sep; 11(1):4909. PubMed ID: 32999291
[TBL] [Abstract][Full Text] [Related]
15. Precise Delivery of Nanomedicines to M2 Macrophages by Combining "Eat Me/Don't Eat Me" Signals and Its Anticancer Application.
Tang Y; Tang Z; Li P; Tang K; Ma Z; Wang Y; Wang X; Li C
ACS Nano; 2021 Nov; 15(11):18100-18112. PubMed ID: 34751571
[TBL] [Abstract][Full Text] [Related]
16. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.
Zhang M; Hutter G; Kahn SA; Azad TD; Gholamin S; Xu CY; Liu J; Achrol AS; Richard C; Sommerkamp P; Schoen MK; McCracken MN; Majeti R; Weissman I; Mitra SS; Cheshier SH
PLoS One; 2016; 11(4):e0153550. PubMed ID: 27092773
[TBL] [Abstract][Full Text] [Related]
18. Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy.
Ramesh A; Kumar S; Nguyen A; Brouillard A; Kulkarni A
Nanoscale; 2020 Jan; 12(3):1875-1885. PubMed ID: 31903467
[TBL] [Abstract][Full Text] [Related]
19. TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets.
Lin GHY; Chai V; Lee V; Dodge K; Truong T; Wong M; Johnson LD; Linderoth E; Pang X; Winston J; Petrova PS; Uger RA; Viller NN
PLoS One; 2017; 12(10):e0187262. PubMed ID: 29084248
[TBL] [Abstract][Full Text] [Related]
20. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment.
Iwamoto C; Takenaka K; Urata S; Yamauchi T; Shima T; Kuriyama T; Daitoku S; Saito Y; Miyamoto T; Iwasaki H; Kitabayashi I; Itoh K; Kishimoto J; Kohda D; Matozaki T; Akashi K
Exp Hematol; 2014 Mar; 42(3):163-171.e1. PubMed ID: 24269920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]